Open AccessProton Pump Inhibitor Use and the Antifracture Efficacy of Alendronate
Author(s) -
Bo Abrahamsen,
Pia Eiken,
Richard Eastell
Publication year - 2011
Publication title -
archives of internal medicine
Language(s) - English
Resource type - Journals
eISSN - 1538-3679
pISSN - 0003-9926
DOI - 10.1001/archinternmed.2011.20
Subject(s) - medicine , proton pump inhibitor , bisphosphonate , alendronic acid , hazard ratio , hip fracture , confidence interval , population , osteoporosis , environmental health
Proton pump inhibitors (PPIs) are widely used in elderly patients and are frequently coadministered in users of oral bisphosphonates. Biologically, PPIs could affect the absorption of calcium, vitamin B(12), and bisphosphonates and could affect the osteoclast proton pump, thus interacting with bisphosphonate antifracture efficacy. Moreover, PPIs themselves have been linked to osteoporotic fractures.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom